Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Rumored Trump VP Contender JD Vance Defends Him At Hush Money Trial—Here’s Who Else Is On Trump’s Likely VP Shortlist
Michael Cohen Testifying Today: How He Went From Lawyer Who’d ‘Take A Bullet’ For Trump To Prosecutors’ Key WitnessNovo Nordisk’s weight loss injection semaglutide — the ingredient inside its wildly popular drugs Ozempic and Wegovy — could slash the risk of heart attacks and strokes whether patients lose weight when taking it or not, according to new research, a finding that bolsters thePatients taking semaglutide had a 20% lower risk of heart attack, stroke or death due to cardiovascular...
University College London’s professor John Deanfield, who led the study, said the “findings have important clinical implications” and suggests semaglutide has another mechanism to lower cardiovascular risk other than reducing unhealthy body fat, adding that many more patients than are taking it now would likely benefit from the drug.
Semaglutide Ozempic Wegovy Cardiovascular Heart Obesity Maintain Weight Loss Novo Nordisk
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Weight loss wonder drug sparks 'Ozempic babies' phenomenonA new phenomenon of women having surprise pregnancies while taking weight loss medications like Ozempic and Wegovy is happening.
Baca lebih lajut »
Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug FrenzyI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Baca lebih lajut »
Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug FrenzyI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Baca lebih lajut »
Bernie Sanders Urges Ozempic Maker Novo Nordisk To Be Fair Over ‘Outrageously Expensive’ U.S. Drug PricesRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Baca lebih lajut »
TikTok Sensation: Ozempic, a Prescription Drug for Type 2 Diabetes, Goes ViralOzempic, a prescription drug used to manage blood sugar levels in diabetic adults, has gained popularity on TikTok due to its weight loss side effect. Celebrities and influencers have endorsed the drug, leading to over 250 million views on the platform. Combined with a weight-loss program and calorie-restricted diet, patients can potentially lose between 20 and 100 pounds.
Baca lebih lajut »
President Biden’s Latest Attack On The Economy: Smother The InternetSteve Forbes is Chairman and Editor-in-Chief of Forbes Media.
Baca lebih lajut »